Genotyping of patients treated with selective serotonin reuptake inhibitors. / Genotyping av pasienter behandlet med selektive serotoninreopptakshemmere.
Tidsskr Nor Laegeforen
; 142(13)2022 09 27.
Article
em En, Nor
| MEDLINE
| ID: mdl-36164782
ABSTRACT
BACKGROUND:
Selective serotonin reuptake inhibitors (SSRIs) are used by over 180,000 people in Norway. The enzymes CYP2D6 and CYP2C19 are key in the metabolism of SSRI antidepressants. The serotonin transporter coded by SLC6A4 may be significant for the efficacy of the drugs. MATERIAL ANDMETHOD:
All patients who had undergone genotyping for CYP2D6, CYP2C19 and SLC6A4 at the Centre for Psychopharmacology in 2020 were included, irrespective of indication. For those patients where data were available, CYP2C19 genotype was linked to serum concentration measurement of escitalopram, which is the most commonly used SSRI drug.RESULTS:
Out of 3,492 patients, 432 (12.4 %) had a combination of genotypes of CYP2D6, CYP2C19 and SLC6A4 considered to lead to the most favourable metabolism and efficacy of SSRI antidepressants. The dose requirement in patients with poor CYP2C19 metabolism was more than halved to achieve the same concentration of escitalopram compared to patients with normal metabolism.INTERPRETATION:
Our findings demonstrate the low prevalence of the most favourable genotype combination for response to SSRIs. Genotype combinations probably contribute to the wide variation between individuals in the efficacy of these drugs and the fact that treatment does not produce the desired outcome in many patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores Seletivos de Recaptação de Serotonina
/
Citocromo P-450 CYP2D6
/
Proteínas da Membrana Plasmática de Transporte de Serotonina
/
Citocromo P-450 CYP2C19
/
Escitalopram
/
Antidepressivos
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
/
Nor
Revista:
Tidsskr Nor Laegeforen
Ano de publicação:
2022
Tipo de documento:
Article